Drug delivery

Brain and Spinal Tumors of Childhood

Volumn , Issue , 2004, Pages 228-242

  Blaney, Susan M ^a   Berg, Stacey L ^a   Boddy, Alan V ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84983589365     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (163)

1. Bradbury M. The blood-brain barrier. Exp Physiol 1993; 78:53-72.
2. De Boer A, Breimer D. The blood-brain barrier: Clinical implications for drug delivery to the brain. J R Coll Phys Lond 1994; 28:502-6.
3. Johansson B. The physiology of the blood-brain barrier. AdvExp Med Biol 1990; 27:25-39.
4. Patel M, Blaney S, Balis F. Pharmacokinetics of drug delivery to the central nervous system. In: Grochow L, Ames M (eds). A Clinician's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. Baltimore: Williams ft Wilkins, 1998, pp. 67-90.
5. Bart J, Groen HJ, Hendrikse N, van der Graaf W, Vallburg W, de Vries EG. The blood-brain barrier and oncology: New insights into function and modulation. Cancer Treat Rev 2000; 26:449-62.
6. Rao VV, Dahlheimer JL, Bardgett ME, etal. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 1999; 96:3900-5.
7. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999; 36:179-94.
8. Betz A. An overview of the multiple functions of the blood-brain barrier. NIDA Res Monogr 1992; 120:5-72.
9. Pardridge W, Oldendorf W, Cancilla P, et al. Blood-brain barrier: Interface between internal medicine and the brain. Ann Intern Med 1986; 105:82-95.
10. Angeletti RH, Novikoff PM, Juvvadi SR, Fritschy JM, Meier PJ, Wolkoff AW. The choroid plexus epithelium is the site of the organic anion transport protein in the brain. Proc Natl Acad Sci USA 1997; 94:283-6.
11. Wijnholds J, deLange EC, Scheffer GL, et al. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 2000; 105:279-85.
12. Groothuis D. The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. Neuro-Oncol2000; 2:45-59.
13. Blasberg R, Kobayashi T, Horowitz M, et al. Regional blood-to-tissue transport in ethylnitrosourea-induced brain tumors. Ann Neurol 1983; 14:202-15.
14. Burger P. The anatomy of astrocytomas. Mayo Clin Proc 1987; 62:527-9.
15. Poplack D, Bleyer W, Horowitz M. Pharmacology of AntineoplasticAgents in Cerebrospinal Fluid. New York: Plenum Press, 1980.
16. Mellet L. Physiochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system. Cancer Treat Rep 1977; 61:527-31.
17. Koch-Weser J, Sellers E. Binding of drugs to serum albumin. N Engl J Med 1976; 294:311-16.
18. Stewart D. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neuro-Oncol1994; 20:121-39.
19. Vick NA, Khandekar J. Chemotherapy of brain tumors: The "blood-brain" barrier is not a factor. Arch Neurol 1977; 34:523-6.
20. Doolittle N, Petrillo A, Bell S, Cummings P, Eriksen S. Blood-brain barrier disruption for the treatment of malignant brain tumors: The National Program. J Neuroscience Nurs 30:81-90.
21. Neuwelt E, Rapoport S. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed Proc1984; 43:214-19.
22. Shapiro WR, Voorhies RM, Hiesiger EM, Sher PB, Basler GA, Lipschutz LE. Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: A quantitative autoradiographic study. Cancer Res 1988; 48:694-701.
23. Hiesiger EM, Voorhies RM, Basler GA, Lipschutz LE, Posner JB, Shapiro WR. Opening the blood-brain and blood-tumor barriers in experimental rat brain tumors: The effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann Neurol 1986; 19:50-9.
24. Zunkeler B, Carson RE, Olson J, et al. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 1996; 85:1056-65.
25. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000; 88:637-47.
26. Williams PC, Henner WD, Roman-Goldstein S, et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 1995; 37:17-27, 27-8.
27. Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 2001; 7:493-500.
28. Fortin D, McCormick CI, Remsen LG, Nixon R, Neuwelt EA. Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model. Neurosurgery 2000; 47:199-207.
29. Elliott PJ, Hayward NJ, Huff MR, Nagle TL, Black KL, Bartus RT. Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy. Exp Neurol 1996; 141:214-24.
30. Liu Y, Hashizume K, Chen Z, et al. Correlation between bradykinin-induced blood-tumor barrier permeability and B2 receptor expression in experimental brain tumors. Neurol Res 2001; 23:379-87.
31. Cloughesy TF, Black KL, Gobin YP, et al. Intra-arterial Cereport (RMP-7) and carboplatin: A dose escalation study for recurrent malignant gliomas. Neurosurgery 1999; 44:270-8, 278-9.
32. Gutman M, Laufer R, Eisenthal A, et al. Increased microvascular permeability induced by prolonged interleukin-2 administration is attenuated by the oxygen-free-radical scavenger dimethylthiourea. Cancer Immunol Immunother1996; 43:240-4.
33. Black KL, Chio CC. Increased opening of blood-tumour barrier by leukotriene C4 is dependent on size of molecules. Neurol Res 1992; 14:402-4.
34. De Vries H, Blom-Roosemalen M, van Oosten M, et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol 1996; 64:37-43.
35. Raymond J, Robertson D, Dinsdale H. Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier. Can J Neurol Sci 1986; 13:214-20.
36. Inamura T, Black K. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 1984; 14:862-70.
37. Emerich DF, Dean RL, Osborn C, Bartus RT. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: From concept to clinical evaluation. Clin Pharmacokinet 2001; 40:105-23.
38. Thomas J, Lind M, Ford J, Bleehen N, Calvert A, Boddy A. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumors. Cancer Chem Pharmacol 2000; 45:284-90.
39. Trnovec T, Kallay Z, Bezek S. Effects of ionizing radiation on the blood-brain barrier permeability to pharmacologically active substances. Int J Radiat Oncol Biol Phys 1990; 19:1581-7.
40. Qin DX, Zheng R, Tang J, Li JX, Hu YH. Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys 1990; 19:1507-10.
41. Schinkel A. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999; 36:179-94.
42. Balis FM, Holcenberg JS, Blaney SM. General principles of chemotherapy. In: Pizzo P, Poplack D (eds). Principles and Practice of Pediatric Onoclogy, 4th edition. Philadelphia: Lippincott-Raven, 2002, pp. 237-309.
43. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump in human hematopoietic stem cell. Cell 1991; 66:85-94.
44. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97:2517-24.
45. Warren KE, Patel MC, McCully CM, Montuenga LM, Balis FM. Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates. Cancer Chemother Pharmacol 2000; 45:207-12.
46. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-8.
47. Zucchetti M, Boiardi A, Silvani A, Parisi I, Piccolrovazzi S, D'Incalci M. Distribution of daunorubicin and daunorubicinol In human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother Pharmacol 1999; 44:173-6.
48. Koukourakis MI, Koukouraki S, Fezoulidis I, et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer 2000; 83:1281-6.
49. Poplack D, Riccardi R. Pharmacologic approaches to the treatment of central nervous system malignancy. In: Poplack D, Massimo L, Cornaglia-Ferraris P (eds). The Role ofPharmacology in Pediatric Oncology. Boston: Martinus Nijhoff, 1987, pp. 137-56.
50. Chabner B. The role of drugs in cancer treatment. In: Chabner B (ed.). Pharmacologic Principles of Cancer Treatment. Philadelphia: Wb Saunders, 1982, pp. 3-14.
51. Collins J. Regional therapy: An overview. In: Poplack D, Massimo L, Cornaglia-Ferraris P (eds). The Role of Pharmacology in Pediatric Oncology. Boston: Martinus Nijhoff, 1987, pp. 125-35.
52. Blasberg R, Patlak C, Fernstermacher J. Intrathecal chemotherapy. Brain tissue profiles after ventriculo-cisternal perfusion. J Pharmacol Exp Ther 1975; 195:73-83.
53. Blaney S, Poplack D, Godwin K, McCully C, Murphy R, Balis F. The effect of body position on ventricular cerebrospinal fluid methotrexate concentration following intralumbar administration. J Clin Oncol 1995; 13:177-9.
54. Bomgaars L, Chamberlain M, Poplack D, Blaney S. Leptomeningeal metastases. In: Levin VA (ed.): Cancer in the Nervous System, 2nd edition. New York: Oxford University Press, 2002, pp. 375-93.
55. Larson S, Johnson G, Ommaya A, Jones A, Chiro GD. The radionuclide ventriculogram. J Am Med Assoc 1973; 224:853-7.
56. Bleyer W. Clinicalpharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 1977; 61:1419-25.
57. Bleyer W, Coccia PF, Sather HN, et al. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol 1983; 1:317-25.
58. Heideman R, Packer R, Reaman G, et al. A Phase II evaluation of thiotepa in central nervous system malignancies. Cancer1992; 72:271-5.
59. Witham T, Fukui M, Meltzer C, Burns R, Konziolka D, Bozik M. Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis. Cancer 1999; 86:1347-53.
60. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993; 11:561 -9.
61. Berg S, Balis F, Zimm S, et al. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 1992; 10:143-8.
62. Adamson P, Balis F, Arndt C, et al. Intrathecal 6-mercaptopurine: Preclinical pharmacology, phase I/II trial, and pharmacokinetic study. Cancer Res 1991; 51:6079-83.
63. Blaney S, Balis F, Arndt A, et al. A phase I study of intrathecal mafosfamide (MF) in patients wtih refractory meningeal malignancies. Proc Am Soc Clin Oncol 1992; 11:113.
64. Slave I, Schuller E, Czech T, Hainfellner J, Seidl R, Dleckmann K. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neuro-Oncol 1998; 38:213-18.
65. Blaney S, Heideman R, Cole D, et al. A phase I study of intrathecal topotecan. Proc Am Soc Cancer Res 1998; 39:2198
66. Glantz M, Jaekle K, Chamberlain M, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res1999; 5:2294-402.
67. Bomgaars L, Geyer J, Franklin J, et al. A phase I dose escalation study of intrathecal DepoFoam™ encapsulated cytarabine (DTC101) in pediatric patients with advanced malignancies. Am Soc Ped Hem Oncol 1998; 30:683.
68. Jaeckle K, Phuphanich S, Bent M, et al. Intrathecal treatment ol neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001; 84:157-63.
69. Menei P, Benoit JP, Boisdron-Celle M, Fournier D, Mercier P, Guy G. Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery 1994; 34:1058-64.
70. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet1995; 345:1008-12.
71. Haroun RI, Brem H. Local drug delivery. Curr Opin Oncol 2000; 12:187-93.
72. Subach B, Witham T, Kondziokla D, Lunsford L, Bozik M, Schiff D. Morbidity and survival after 1,3-bis (2-chloroethyl)-1-nitrosourea water implantation for recurrent glioblastoma: A retrospective case-matched cohort series. Neurosurgery1999; 45:17-23.
73. Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol 2000; 53:458-64.
74. Bobo R, Laske DW, Akbasak A, Morrison P, Dedrick R, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994; 91:2076-80.
75. Friedman HS, Dolan ME, Moschel RC, et al. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst 1992; 84:1926-31.
76. Dolan ME, Mitchell RB, Mummert C, Moschel RC, Pegg AE. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 1991; 51:3367-72.
77. Olivi A, Bruce J, Saris S, et al. Phase I study of escalating doses of interstitial BCNU administered via wafer in patients with recurrent malignant glioma. Proc Am Soc Clin Oncol 1998; 17:A1490.
78. Menei P, Venier MC, Gamelin E, et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: A pilot study. Cancer1999; 86:325-30.
79. Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 2000; 47:1391-8, 1398-9.
80. Fernstermacher J, Kaye T. Drug "diffusion" within the brain. Ann N Y Acad Sci 1988; 531:29-39.
81. Rosenberg G, Kyner W, Estrada E. Bulk flow of brain interstitial fluid under normal and hyperosmolar conditions. Am J Physiol1980; 238:F42-9.
82. Laske DW, Morrison PF, Lieberman DM, et al. Chronic interstitial infusion of protein to primate brain: Determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg1997; 87:586-94.
83. Lieberman D, Laske DW, Morrison PF, Bankiewicz K, Oldfield EH. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995; 82:1021 -9.
84. Viola JJ, Agbaria R, Walbridge S, et al. In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors. Cancer Res 1995; 55:1306-9.
85. Heimberger A, Archer G, McLendon RE, et al. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin Cancer Res 2000; 6:4148-53.
86. Saris SC, Blasberg RG, Carson RE, et al. Intravascular streaming during carotid artery infusions. Demonstration in humans and reduction using diastole-phased pulsatile administration. J Neurosurg 1991; 74:763-72.
87. Shapiro WR. Chemotherapy of malignant gliomas: Studies of the BTCG. Rev Neurol (Paris) 1992; 148:428-34.
88. Berg S, Poplack D. Advances in the treatment of meningeal cancers. Crit Rev Oncol Hematol 1995; 20:87-98.
89. Abrey LE, Rosenblum MK, Papadopoulos E, Childs BH, Finlay JL. High dose chemotherapy with autologous stem cell rescue in adults with malignant primary brain tumors. J Neuro-Oncol1999; 44:147-53.
90. Papadakis V, Dunkel IJ, Cramer LD, et al. High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors. Bone Marrow Transplant 2000; 26:153-60.
91. Kochi M, Ushio Y. High-dose chemotherapy with autologous hematopoietic stem-cell rescue for patients with malignant brain tumors. Crit Rev Neurosurg 1999; 9:295-302.
92. Finlay J, Stewart S, Wong M, et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. J Clin Oncol 1996; 14:2495-503.
93. Guruangan S, Dunkel IJ, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol1998; 16:2486-93.
94. Colvin M, Chabner B. Alkylating agents. In: Chabner B, Collins JM (eds). Cancer Chemotherapy: Principles and Practice. Philadelphia: Jb Lippincott, 1990, pp. 276-313.
95. Frei E, Teicher B, Holden S, Cathcar K, Wang Y. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988; 48:6417-23.
96. Connors T. Alkylating drugs, nitrosoureas and dimethyl-triazenes. In: Pinedo HM (ed.). Cancer Chemotherapy. New York: Elsevier, 1981, pp. 32-47.
97. Mirkes P. Cyclophosphamide teratogenesis: A review. Teratog Carcinog Mutagen 1985; 5:75-88.
98. Balis FM, Holcenberg JS, Blaney SM. General principles of chemotherapy. In: Pizzo P, Poplack D (eds). Principles and Practice of Pediatric Oncology, 4th edition. Philadelphia: Lippincott-Raven, 2002, pp. 237-309.
99. Abrahamsen TG, Lange BJ, Packer RJ, et al. A phase I and II trial of dose-intensified cyclophosphamide and GM-CSF in pediatric malignant brain tumors. J Pediatr Hematol Oncol1995; 17:134-9.
100. Yule SM, Foreman NK, Mitchell C, Gouldon N, May P, McDowell HP. High-dose cyclophosphamide for poor-prognosis and recurrent pediatric brain tumors: A dose-escalation study. J Clin Oncol 1997; 15:3258-65.
101. Allen JC, Helson L. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 1981; 55:749-56.
102. Kumar A, Renaudin J, Wilson C, Boldrey E, Enot K, Levin V. Procarbazine hydrochloride in the treatment of brain tumors. J Neurosurg 1974; 40:365-71.
103. Chintagumpala M, Burger P, McCluggage C, et al. Response to procarbazine in newly diagnosed patients with high-grade glioma: A Pediatric Oncology Group (POG) study. Proc Annu Meet Am Soc Clin Oncol 1999; 18:A2153.
104. Galanis E, Buckner JC, Burch PA, et al. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. J Clin Oncol 1998; 16:2953-8.
105. Edwards M, Levin V, Wilson C. Brain tumor chemotherapy: An evaluation of agents in current use for phase II and III trials. Cancer Treat Rep 1980; 64:1179-205.
106. Newton H, Bromberg J, Junck L, Page M, Greenberg H. Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. J Neuro-Oncol 1993; 15:257-63.
107. Friedman H, Kokkinakis D, Pluda J, et al. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 1998; 16:3570-5.
108. Schilsky R, Dolan M, Bertucci D, et al. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res2000; 6:3025-31.
109. Agarwala S, Kirkwood J. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000; 5:144-51.
110. Newlands ES, O'Reilly SM, Glaser MG, et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996; 32A:2236-41.
111. Bower M, Newlands ES, Bleehen NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997; 40:484-8.
112. Friedman H, Pluda J, Quinn J, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000; 18:3522-8.
113. Patel M, Godwin K, McCully C, Adamson P, Balis F. Plasma and cerebrospinal fluid pharmacokinetics of carboplatin and cisplatin. Proc Am Assoc Cancer Res 1996; 37:A2753.
114. Van den Bent M, Schellens J, Vecht C, et al. Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas. Eur J Cancer 1998; 34:1570-4.
115. Murry D. Comparative clinical pharmacology of cisplatin and carboplatin. Pharmacotherapy 1997; 17:140-455.
116. Bertolone SJ, Baum ES, Krivit W, Hammond GD. A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Childrens Cancer Study Group. J Neuro-Oncol 1989; 7:5-11.
117. Khan A, D'Souza B, Wharam M, et al. Cisplatin therapy in recurrent childhood brain tumors. Cancer Treat Rep 1982; 66:2013-20.
118. Sexauer C, Khan A, Burger P, et al. Cisplatin in recurrent pediatric brain tumors: A POG phase II study. Cancer 1985; 56:1497-501.
119. Walker RW, Allen JC. Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol 1988; 6:62-6.
120. Whittle I, Malcolm G, DI DJ, Reid M. Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin. Br J Neurosurg 1999; 13:132-7.
121. Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17:1141-5.
122. Allen JC, Walker R, Luks E, Jennings M, Barfoot S, Tan C. Carboplatin and recurrent childhood brain tumors. J Clin Oncol 1987; 5:459-63.
123. Gaynon PS, Ettinger LJ, Moel D, et al. Pediatric phase I trial of carboplatin: A Children's Cancer Study Group report. Cancer Treat Rep 1987; 71:1039-42.
124. Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD. Carboplatin in childhood brain tumors. A Children's Cancer Study Group phase II trial. Cancer 1990; 66:2465-9.
125. Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: A Pediatric Oncology Group randomized phase II study. J Clin Oncol 1992; 10:249-56.
126. Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 1993; 11:850-6.
127. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 1999; 17:2127-36.
128. Mahoney DH, Jr., Cohen ME, Friedman HS, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: A Pediatric Oncology Group phase II study. Neuro-Oncol 2000; 2:213-20.
129. Kobrinsky NL, Packer RJ, Boyett JM, et al. Etoposide with or without mannitol for the treatment of recurrent or primarily unresponsive brain tumors: A Children's Cancer Group Study, CCG-9881. J Neuro-Oncol 1999; 45:47-54.
130. Ashley DM, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol1996; 14:1922-7.
131. Chamberlain MC. Recurrent cerebellar gliomas: Salvage therapy with oral etoposide. J Child Neurol 1997; 12:200-4.
132. Chamberlain MC. Recurrent intracranial ependymoma in children: Salvage therapy with oral etoposide. Pediatr Neurol2001; 24:117-21.
133. Korones DN, Fisher PG, Cohen KJ, Dubowy RL. No responses to oral etoposide in 15 patients with recurrent brain tumors. Med Pediatr Oncol 2000; 35:80-2.
134. Needle MN, Molloy PT, Geyer JR, et al. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 1997; 29:28-32.
135. Sullivan MP, van Eys J, Herson J, Starling KA, Ragab A, Sexhauer C. Nonresponsiveness of brain tumors to VM-26 therapy in children. Cancer Treat Rep 1979; 63:155-6.
136. Seiler RW. Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors of children. Helv Paediatr Acta 1980; 35:51-6.
137. Blaney S, Cole D, Balis F, Godwin K, McCully C, Poplack D. Plasma and CSF pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1992; 53:725-7.
138. Sung C, Blaney S, Cole D, Balis F, Dedrick R. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 1994; 54:5118-22.
139. Friedman H, Houghton P, Schold S, Keir S, Bigner D. Activity of 9-dimethylamiomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chem Pharmacol 1994; 34:171-4.
140. Blaney S, Phillips P, Packer R, et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996; 78:527-31.
141. Kadota R, Stewart C, Horn M, et al. Topotecan for the treatment of recurrent or progressive central nervous system tumors: A Pediatric Oncology Group phase II study. J Neuro-Oncol 1999; 43:43-7.
142. Blaney S, Balis F, Cole D, et al. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993; 53:1032-6.
143. Furman W, Baker S, Pratt CB, Rivera G, Evans WE, Stewart C. Escalating systemic exposure to topotecan following a 120-hour continuous infusion in children with relapsed acute leukemia. J Clin Oncol 1996; 14:1504-11.
144. Stewart C, Baker S, Heideman R, Jones D, Crom W, Pratt C. Clincal pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity. J Clin Oncol 1994; 12:1946-54.
145. Rosing H, Herben V, van Gortel-van Zomeren D, et al. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemother Pharmacol 1997; 39:498-504.
146. Zamboni W, Gajjar A, Heideman R, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998; 4:783-9.
147. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin. Cancer Res 1987; 47:5944-7.
148. Friedman H, Petrow W, Friedman A, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999; 17:1516-25.
149. Murry D, Cherrick I, Salama V, et al. Influence of phenytoin on the disposition of irinotecan: A case report. J Pediatr Hematol Oncol 2002; 24:130-3.
150. Rosenstock J, Evans A, Schut L. Response to vincristine of recurrent brain tumors in children. J Neurosurg 1976; 45:135-9.
151. Rosen G, Ghavimi F, Nirenberg A, Mosende C, Mehta BM. High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children. Cancer Treat Rep 1977; 61:681-90.
152. Mulne AF, Ducore JM, Elterman RD, et al. Oral methotrexate for recurrent brain tumors in children: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 2000; 22:41 -4.
153. Koehler PJ. Use of corticosteroids in neuro-oncology. Anticancer Drugs 1995; 6:19-33.
154. Straathof CS, van den Bent MJ, Ma J, et al. The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor. J Neuro-Oncol 1998; 37:1-8.
155. Ostergaard L, Hochberg FH, Rabinov JD, et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 1999; 90:300-5.
156. Kirsch M, Schacker G, Black P. Anti-angiogenic treatment strategies for malignant brain tumors. J Neuro-Oncol 2000; 50:149-63.
157. Deininger M, Goldman J, Lydon N, Melo J. The tryosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 1997; 90:3691-8.
158. Druker B, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6.
159. Buchdunger E, Cioffi C, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-45.
160. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90:4947-52.
161. Heinrich M, Griffith D, Druker B, Wait C, Ott K, Ziggler A. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96:925-32.
162. Nistér M, Claesson-Welch L, Eriksson A, Heldin C-H, Westermark B. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem 1991; 266:16755-63.
163. Balis FM, Poplack DG. Cancer Chemotherapy. In: Nathan DG, Oski FA (eds). Hematology of Infancy and Childhood. Philadelphia: W.B. Saunders, 1993, pp. 1207-38.